Alverin

Quick links to important sections

Alverin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alverin

Property Description
Active ingredient Alverine Citrate
Form Hard Capsules or Soft Gel Capsules
Pharmacological class Antispasmodic Agent; Smooth Muscle Relaxant
Common use Relief of pain and spasms in the digestive tract
Origin Synthetic Compound

Alverin: A Definition and Pharmacological Classification

Alverin, identified by the International Nonproprietary Name (INN) Alverine Citrate, is a synthetic pharmaceutical agent primarily classified as a Smooth Muscle Relaxant and an Antispasmodic Agent. This oral medication belongs to the tertiary amine group, intended to counteract involuntary muscle contractions within the gastrointestinal system. Its classification defines its role as an agent dedicated to managing the muscular overactivity associated with various functional digestive disorders. Alverine’s primary therapeutic role is to help relax the muscles in the gut, a function clinically recognized for its efficacy in relieving abdominal discomfort.

Composition, Form, and General Purpose

The active component, Alverine Citrate, is a fully synthetic compound derived from Alverine, which is typically prepared for oral delivery in the form of Hard Capsules or soft gel capsules. Alverine Citrate is commonly available as a single-entity product, but also as a Combination product frequently paired with an antifoaming agent such as Simethicone. This combination, a distinguishing feature from some older antispasmodics, allows the medicine to target both muscle spasm and the physical discomfort caused by trapped gas. The general purpose of this medicine is to alleviate the pain and distress caused by intense internal cramping and spasms of the gut wall, thereby providing functional relief from the physical manifestations of intestinal hyperactivity.

How Does Alverine Citrate Act on the Muscle?

Alverine Citrate achieves its therapeutic effect by functioning as a direct myotropic antispasmodic, meaning its action is concentrated directly on the smooth muscle cells of the digestive tract. The primary principle involves modulating the contractility of these cells, a mechanism that decreases the sensitivity of smooth muscle contractile proteins to calcium. This direct action on the musculature, rather than indirectly via neural pathways, differentiates it from certain other antispasmodic classes, allowing it to specifically target the source of the cramp.

What side effects are possible with Alverin?

Possible Side Effects and Safety Information

The safety profile for Alverine Citrate is defined by documented adverse reactions and specific regulatory constraints detailed in official prescribing information.

Adverse Reaction Classification

All adverse reactions officially listed in regulatory documents are assigned a frequency classification of Not Known. This designation indicates that the frequency of these effects cannot be accurately estimated from available post-marketing data.

Adverse reactions are formally grouped by the body system affected, known as System-Organ Classes (SOCs):

  • Nervous System Disorders: Includes dizziness and headache.
  • Gastrointestinal Disorders: Includes nausea.
  • Skin and Subcutaneous Tissue Disorders: Includes rash and itching.
  • Respiratory, Thoracic and Mediastinal Disorders: Includes dyspnoea (difficulty breathing) and wheezing.
  • Immune System Disorders: Includes allergic reaction and anaphylaxis.
  • Hepatobiliary Disorders: Includes abnormal liver function tests and jaundice due to hepatitis.

Serious Safety Considerations

The most serious adverse reactions documented in regulatory sources are anaphylaxis and the liver disorder jaundice due to hepatitis. Jaundice associated with Alverine is noted to typically resolve upon the cessation of the medication.

Safety Restrictions and Specific Populations

Official labeling specifies that the medicine is contra-indicated in individuals with known hypersensitivity to the drug, or those with underlying conditions such as paralytic ileus or intestinal obstruction. Use is not recommended in children below 12 years of age or during pregnancy and lactation. Furthermore, caution is advised due to the potential for dizziness, which may affect attention and coordination.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation describes the overdose profile of Alverine Citrate based on the observed clinical manifestations and required emergency response. Suspected overdosage, particularly involving very high doses, is classified as potentially fatal and requires immediate medical attention.

Documented Clinical Manifestations

Overdose may present with signs related to systemic vasodilation and anticholinergic overactivity. These include severe hypotension (low blood pressure) and a cluster of atropine-like toxic effects. These effects often involve the central nervous system, manifesting as confusion, hallucinations, dizziness, dilated pupils, and changes to the cardiovascular system, such as a fast heart rate. Other documented presentations include blurred vision, dry mouth, and nausea.

When to Seek Immediate Medical Help

It is mandated that individuals experiencing or suspecting an overdose contact a doctor or the nearest hospital emergency department immediately. When seeking help, the regulatory guidance states to take the product box and any remaining capsules with you.

Officially Documented Management

No specific antidote is known for Alverine Citrate overdose. Management procedures are supportive, focusing on treating the symptoms presented. The officially documented approach for clinical management follows the established principles for treating atropine poisoning.

Therapeutic Uses of Alverin

What Alverin Treats: Main Uses and Benefits

Alverine is relevant in contexts marked by increased discomfort or tension and is used in situations involving certain distressing symptoms. The medication is commonly used across conditions presenting with acute episodes that involve these types of manifestations.


Ease Discomfort from Sudden Symptom Clusters

Alverine helps address symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort. It is relevant when symptoms cluster into patterns requiring supportive management during difficult episodes. The medication is commonly used across conditions presenting with systemic or localized discomfort and those involving episodic or fluctuating manifestations.

“It provides support that helps ease the overall symptom burden and contributes to easing the overall symptom load during symptomatic phases.”

Supportive Management and Relief of Functional Strain

This medication is applied in contexts where additional symptomatic support is needed, particularly when symptoms create noticeable functional strain or lead to increased discomfort. It is helpful in situations requiring additional symptomatic assistance when symptoms become temporarily overwhelming, providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Supports patients during episodes of Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Alverin (Alverine Citrate) eligibility is defined by official regulatory documentation that specifies who can and cannot use the medicine, based on age, pre-existing conditions, and physiological status.

Classification Population or Condition Status
Age Eligibility Adults and the Elderly Allowed (Established use)
Children under 12 years Not Recommended (Safety/efficacy not established)
Contraindications Paralytic Ileus, Intestinal Obstruction Prohibited (Contraindicated)
Known Hypersensitivity to ingredients Prohibited (Contraindicated)
Reproductive Status Pregnancy and Lactation (Breast-feeding) Prohibited (Contraindicated/Not Recommended)

Eligibility-Related Restrictions

The regulatory labeling dictates that patients who present with certain new or severe symptoms are restricted from taking the medicine without a medical consultation. These include individuals:

  • Aged 40 years or over with new symptoms.
  • Who have experienced symptoms such as passing blood from the bowel, fever, vomiting, unexplained weight loss, or severe constipation.

These restrictions serve to prevent the use of Alverin when symptoms may indicate an underlying, serious condition that requires urgent assessment.

What should I know about interactions with other medicines?

Official Regulatory Interaction Status

The interaction profile for Alverine Citrate, as defined in the dedicated section of government-approved Summary of Product Characteristics (SmPC) and prescribing information, is characterized by a general absence of formal drug-drug interactions.


Drug and Substance Co-Administration

Interaction Category Regulatory Status
Formal Drug-Drug Interactions None are explicitly documented or known in the formal interaction section (Section 4.5).
Metabolic Interactions (CYP) None stated. No interactions based on Cytochrome P450 enzyme inhibition or induction are listed in the official label.
Contraindicated Combinations None stated. No medicinal products are formally prohibited for co-administration.
Timing Separation Rules None stated. No mandatory spacing of administration is specified in the regulatory documentation.

Substance-Related Functional Caution

The only specific regulatory constraint pertains to substance use. Official labeling notes that Alverine Citrate may cause dizziness. Due to the potential for additive effects on the central nervous system, co-administration with alcohol carries a functional caution. Alcohol is a known CNS depressant that can compound this effect, which is the only documented interaction-related restriction outside of the standard drug-drug interaction categories.

The overall interaction structure is defined by the explicit lack of documented pharmacokinetic or pharmacodynamic interactions with other medicines, which simplifies the regulatory profile of Alverine Citrate.

Mechanism of Action

How Alverin Works: Dual Mechanism of Action

Alverine modulates smooth muscle function through a dual mechanistic profile, primarily targeting cells within the gastrointestinal tract. It acts as both a mu-opioid receptor antagonist and an L-type calcium channel blocker.

Its action as a mu-opioid receptor antagonist involves competitive binding at the receptor site, which prevents the subsequent activation of the G i-protein coupled signaling cascade.

Concurrently, the inhibition of L-type calcium channels impedes the influx of extracellular Ca^2+ ions into the cytoplasm. This reduction in intracellular Ca^2+ concentration limits the activation of the myosin light-chain kinase (MLCK) enzyme.

The resulting decrease in myosin phosphorylation and subsequent actin-myosin cross-bridge cycling directly reduces smooth muscle contractility. This modulation affects signal transduction pathways that regulate gut motility at a system level.

Dosage and Administration Information

Official Administration Guidelines

Alverine Citrate is an oral medication supplied as Hard Capsules in strengths of 60 mg and 120 mg. The administration protocol details the proper route, dose limits, and frequency patterns for use in clinical practice.

Dosage and Frequency

For adults, including the elderly, the standard dose is 60 mg or 120 mg of Alverine Citrate, administered one to three times daily. This regimen establishes the maximum frequency and total dose limits for daily intake.

Contextual Use and Preparation

Alverine capsules must be swallowed whole with water, as they are not designed to be opened or crushed. The administration time relative to food may differ based on the specific product formulation: certain instructions specify taking the capsule at the beginning of meals.

Specific Population Rules

Use of the medicine is not recommended for children below the age of 12 years. Older adults follow the standard adult dosing regimen, as no specific dose adjustment for this population is required.

Procedural Constraints

If a dose is missed by more than four hours, the standard protocol is to skip the forgotten dose and continue with the next scheduled dose; a double dose should not be taken. A further constraint on the duration of use involves consulting a healthcare professional if symptoms fail to improve after two weeks of treatment.

Recent Clinical Evidence

Research Evidence for Alverin


Evidence from Trials in Irritable Bowel Syndrome (IBS)

The clinical evaluation of Alverin has largely focused on its use in conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome (IBS). Researchers used Randomized Controlled Trials (RCTs), where study participants are randomly assigned to receive either Alverin or a placebo (an inactive treatment), to explore how symptoms change over time. Research examined outcomes related to physical discomfort, exploring changes in the severity and frequency of patient-reported outcomes describing perceived discomfort. Outcomes reflecting daily functioning or overall activity level were also monitored.

Research examined both Alverin as a single agent and as a combination product, frequently paired with Simethicone. Some trials, particularly those using the combination product, described patterns in which symptom measurements differed from the measurements reported by the placebo group for outcomes related to perceived discomfort. However, research exploring Alverin alone sometimes described patterns where findings were mixed or showed little difference from the placebo group. The complexity of the evidence is highlighted by the high placebo response rate that is often observed in IBS trials.

Evidence in Other Spasmodic Conditions and Research Gaps

Alverin was evaluated in other contexts relevant in trials assessing short-term or episodic symptom patterns, primarily conditions involving periods of heightened symptoms. Research examined Alverin's use for painful spasms related to diverticular disease of the colon and primary dysmenorrhoea. Studies monitored physiological strain or stress, specifically examining the change in reported pain and spasm severity in patients presenting with acute or disruptive episodes. Official documentation outlines the contexts in which the medicine was evaluated in, but the current evidence base includes a limited number of recent, dedicated RCTs for these specific diagnoses, and sample sizes were modest in some studies.

Long-term effects are not fully established as studies observing responses over defined time intervals were often short. Data describing the outcomes related to extended use beyond twelve weeks are not well characterized. Furthermore, evidence quality varies across studies, and results apply only to the populations studied, with limited information or comparative evidence lacking for its use in pediatric populations or in older adults.

Frequently Asked Questions (FAQ)

Common questions about Alverin (FAQ)


Q: Does alcohol consumption need to be avoided completely while taking Alverin?

Official labeling advises caution regarding the use of alcohol with this medicine. Alverin may cause dizziness, and because alcohol can compound this effect on the central nervous system, official labeling notes the potential for enhanced effects, which generally leads to advice to limit or avoid consumption.


Q: Does Alverin cause tiredness or affect my ability to drive?

The official product information notes that the medicine may cause dizziness, which could affect attention and coordination. If a person experiences dizziness, it is advised not to drive or operate machinery. Tiredness is not listed as a documented adverse reaction in the regulatory materials.


Q: What kind of studies have been performed on Alverin?

Research has focused primarily on Randomized Controlled Trials (RCTs) to explore the effects of Alverin on symptoms. These studies have examined its use in conditions like Irritable Bowel Syndrome (IBS), painful diverticular disease, and primary dysmenorrhoea. Alverin has been evaluated both alone and as a combination product with Simethicone.


Q: What does official guidance say about Alverin use in older adults?

Regulatory documents state that the standard adult dose is specified for older adults, as no specific dose adjustment is mandated for this population. However, it is noted in research summaries that comparative evidence in this group is sometimes limited.


Q: How is Alverin different from a painkiller?

Alverin is classified as an antispasmodic agent, meaning it is a smooth muscle relaxant. Its primary function is to directly target and relax the muscle spasms and tension in the gut wall, which is the source of the pain, distinguishing its action from general painkillers (analgesics).


Q: Is Alverin known by any other names?

The active ingredient is formally known as Alverine Citrate. It is available internationally under various trade names, which may include Spasmonal or Meteospasmyl (the latter is often a combination product).


Q: How is Alverin different from other anti-spasm drugs?

Alverin is officially described as a myotropic antispasmodic with a dual mechanism of action. This means it works directly on the smooth muscle cells of the gut by modulating calcium handling and also acts as a mu-opioid receptor antagonist (blocker).


Q: Can Alverin help with bloating or just pain?

Official documentation indicates that Alverin is used to relieve multiple symptoms associated with functional bowel disorders. These symptoms typically include both abdominal pain and spasms as well as bloating.


Q: Does Alverin contain an opioid or addictive substance?

Alverin is categorized as an antispasmodic agent and is not classified as an opioid. Although its mechanism involves acting as a mu-opioid receptor antagonist (blocker), this classification indicates it is not a scheduled or controlled drug for addiction potential.


Q: How quickly should I expect Alverin to start working?

Official pharmacokinetic data indicates that the most active form of the medicine reaches its highest concentration in the bloodstream (peak plasma level) typically between 1 and 1frac12 hours after the capsule is taken.


Q: Is it okay to take Alverin long-term?

Official guidance advises consulting a healthcare professional if symptoms do not improve after two weeks of treatment. Regulatory research notes that evidence describing outcomes related to extended use beyond twelve weeks is not fully characterized in the current evidence base.


Q: Are there any common side effects of Alverin that people report?

The frequency of all officially listed adverse reactions, such as dizziness, headache, and nausea, is classified as Not Known. This means that the available data is insufficient to accurately estimate how common or rare these effects are among users.


Q: Is weight gain a potential side effect associated with Alverin?

Weight gain is not listed as a documented adverse reaction in the official regulatory information for Alverin.


Q: Can Alverin make my constipation worse?

Constipation is not listed as a documented adverse reaction of Alverin. However, severe constipation is listed as a symptom that requires assessment by a healthcare professional before this medicine is used.


Q: Does Alverin affect blood pressure or heart rate?

Official documents state that Alverin acts selectively on the smooth muscles of the gut and uterus. At therapeutic doses, it is specifically described as not affecting the heart, blood vessels, or tracheal muscle.


Q: Does taking Alverin affect the results of any common medical tests?

One specific documented adverse reaction is abnormal liver function tests, which may appear as elevated enzyme levels. Official documentation does not list specific effects on other types of general or common medical tests.


Q: Are there allergic reaction symptoms associated with Alverin that I should be aware of?

Official information lists allergic reactions, including serious reactions like anaphylaxis. Other documented symptoms include rash, itching, dyspnoea (difficulty breathing), and wheezing.


Q: Does Alverin cause dry mouth?

Dry mouth is not listed as a documented adverse reaction in the official regulatory information for Alverin.


Q: Has Alverin been studied for conditions outside of its main uses?

Research documentation focuses on its established labeled indications: Irritable Bowel Syndrome (IBS), painful diverticular disease of the colon, and primary dysmenorrhoea. There are no officially published studies or uses for conditions outside of these spasmodic disorders in the regulatory context.


Q: Is there any research on Alverin's potential for overdose?

Official documents include a dedicated section on Overdose. Potential symptoms are noted to include hypotension (low blood pressure) and atropine-like effects. Fatality has been reported following overdose with very high doses.


Q: Can Alverin be crushed or split, according to the manufacturer's advice?

Official administration guidelines state that the capsules must be swallowed whole with water. They are specifically not designed to be opened or crushed.


Q: Is Alverin available without a prescription in some countries?

The legal classification of Alverin (its prescription status) is determined by national regulatory bodies and can vary by country. In some regions, it is classified as a medicine available only from a pharmacy (P), while in others, it may require a full prescription.

How should Alverin be stored and disposed of?

Official Storage and Disposal Instructions

Storage Scope Requirement per Regulatory Labeling
Temperature Store below 25 C to maintain product stability.
Environmental Protection Protect from light and moisture.
Packaging Keep the medicine in its original container (or outer carton).
Child Safety Must be stored out of the sight and reach of children.

Official labeling mandates that Alverine must be stored under controlled conditions to preserve its quality. This includes keeping the product in its original packaging and at a temperature not exceeding 25 C. For disposal, unused or expired Alverine must not be thrown away via wastewater or household waste; instead, patients should dispose of it according to local regulations or return it to a pharmacist for safe handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alverin found in:

A-Z Index: